CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 76% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade Axonics, Inc. - AXNX CFD

Market is not available at the moment

Market information is presented
as of 2023-09-21

  • Summary
Trading Conditions
Spread -
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026151 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026151%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003929 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003929%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Axonics Inc ESG Risk Ratings

High Medium Low Negligible

‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* N/A
Open* N/A
1-Year Change* N/A
Day's Range* N/A
52 wk Range 47.59-79.92
Average Volume (10 days) 535.55K
Average Volume (3 months) 14.34M
Market Cap 2.84B
P/E Ratio -100.00K
Shares Outstanding 50.46M
Revenue 319.85M
EPS -0.67
Dividend (Yield %) N/A
Beta 0.43
Next Earnings Date Oct 30, 2023

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

Date Close Change Change (%) Open High Low

Axonics, Inc. Events

Time (UTC) Country Event
Monday, October 30, 2023

Time (UTC)

10:59

Country

US

Event

Q3 2023 Axonics Inc Earnings Release
Q3 2023 Axonics Inc Earnings Release

Forecast

-

Previous

-
Wednesday, February 28, 2024

Time (UTC)

10:59

Country

US

Event

Q4 2023 Axonics Inc Earnings Release
Q4 2023 Axonics Inc Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 273.702 180.29 111.535 13.82 0.707
Revenue 273.702 180.29 111.535 13.82 0.707
Cost of Revenue, Total 76.037 64.572 44.444 6.49 0.356
Gross Profit 197.665 115.718 67.091 7.33 0.351
Total Operating Expense 338.648 252.098 165.295 94.419 32.844
Selling/General/Admin. Expenses, Total 196.257 138.574 91.681 67.748 13.086
Research & Development 34.41 37.297 29.17 20.181 19.402
Operating Income -64.946 -71.808 -53.76 -80.599 -32.137
Interest Income (Expense), Net Non-Operating 2.699 -7.386 0.761 2.974 0.698
Gain (Loss) on Sale of Assets -0.069 -0.091 -0.041 0
Other, Net -1.874 -2.309 -1.043
Net Income Before Taxes -62.316 -79.285 -54.914 -79.934 -32.482
Net Income After Taxes -59.698 -80.067 -54.915 -79.935 -32.483
Net Income Before Extra. Items -59.698 -80.067 -54.915 -79.935 -32.483
Net Income -59.698 -80.067 -54.915 -79.935 -32.483
Income Available to Common Excl. Extra. Items -59.698 -80.067 -54.915 -79.935 -32.483
Income Available to Common Incl. Extra. Items -59.698 -80.067 -54.915 -79.935 -32.483
Diluted Net Income -59.698 -80.067 -54.915 -79.935 -32.483
Diluted Weighted Average Shares 46.6845 43.0723 36.9813 28.5673 27.8069
Diluted EPS Excluding Extraordinary Items -1.27875 -1.8589 -1.48494 -2.79813 -1.16816
Dividends per Share - Common Stock Primary Issue
Diluted Normalized EPS -0.96367 -1.79091 -1.48422 -2.79813 -1.16816
Depreciation / Amortization 9.383 7.241
Unusual Expense (Income) 22.561 4.414
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 92.894 70.65 85.918 70.384 68.98
Revenue 92.894 70.65 85.918 70.384 68.98
Cost of Revenue, Total 22.704 18.15 22.951 19.124 18.784
Gross Profit 70.19 52.5 62.967 51.26 50.196
Total Operating Expense 104.964 85.016 89.527 86.759 90.409
Selling/General/Admin. Expenses, Total 54.983 54.822 54.088 49.14 49.953
Research & Development 8.949 8.056 8.103 7.936 7.135
Depreciation / Amortization 2.279 2.222 2.271 2.317 2.332
Unusual Expense (Income) 16.049 1.766 2.114 8.242 12.205
Operating Income -12.07 -14.366 -3.609 -16.375 -21.429
Interest Income (Expense), Net Non-Operating 4.424 4.311 3.82 -0.397 -0.479
Net Income Before Taxes -7.646 -10.055 0.143 -16.772 -21.908
Net Income After Taxes -7.342 -9.248 0.665 -16.252 -21.443
Net Income Before Extra. Items -7.342 -9.248 0.665 -16.252 -21.443
Net Income -7.342 -9.248 0.665 -16.252 -21.443
Income Available to Common Excl. Extra. Items -7.342 -9.248 0.665 -16.252 -21.443
Income Available to Common Incl. Extra. Items -7.342 -9.248 0.665 -16.252 -21.443
Diluted Net Income -7.342 -9.248 0.665 -16.252 -21.443
Diluted Weighted Average Shares 49.0884 48.5791 48.1823 47.2082 45.311
Diluted EPS Excluding Extraordinary Items -0.14957 -0.19037 0.0138 -0.34426 -0.47324
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS 0.17308 -0.16674 0.04325 -0.23078 -0.29816
Gain (Loss) on Sale of Assets -0.069
Other, Net 0.001
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 465.075 321.317 327.946 211.68 165.34
Cash and Short Term Investments 357.211 220.878 241.181 183.674 157.524
Cash & Equivalents 238.846 220.878 241.181 171.082 98.306
Short Term Investments 118.365 0 12.592 59.218
Total Receivables, Net 44.817 29.044 18.27 7.879 0.427
Accounts Receivable - Trade, Net 44.817 29.044 18.27 7.879 0.427
Total Inventory 55.765 64.946 63.06 15.659 3.673
Prepaid Expenses 7.282 6.449 5.435 4.468 3.716
Total Assets 659.353 547.945 342.206 219.822 171.906
Property/Plant/Equipment, Total - Net 12.998 14.015 13.428 7.247 2.784
Property/Plant/Equipment, Total - Gross 20.534 19.559 17.243 10.307 4.768
Accumulated Depreciation, Total -7.536 -5.544 -3.815 -3.06 -1.984
Intangibles, Net 86.253 106.469 0.196 0.311 0.426
Other Long Term Assets, Total 0.613 0.634 0.636 0.584 3.356
Total Current Liabilities 65.247 26.868 45.682 12.033 5.887
Accounts Payable 9.07 7.654 10.66 5.882 3.436
Accrued Expenses 23.577 19.214 13.912 6.151 1.683
Notes Payable/Short Term Debt 0 0 0 0 0
Total Liabilities 89.214 65.507 54.836 36.819 28.631
Total Long Term Debt 0 0 0 20.336 22.744
Long Term Debt 0 20.336 19.463
Capital Lease Obligations 3.281
Minority Interest
Total Equity 570.139 482.438 287.37 183.003 143.275
Preferred Stock - Non Redeemable, Net 0 0 0 0
Common Stock 0.005 0.005 0.004 0.003 0.003
Additional Paid-In Capital 969.545 803.559 522.296 363.012 243.337
Retained Earnings (Accumulated Deficit) -374.264 -314.566 -234.499 -179.584 -99.649
Other Equity, Total -25.147 -6.56 -0.431 -0.428 -0.416
Total Liabilities & Shareholders’ Equity 659.353 547.945 342.206 219.822 171.906
Total Common Shares Outstanding 49.5467 46.3302 39.931 34.111 27.8069
Current Port. of LT Debt/Capital Leases 0 21.11 0.768
Other Liabilities, Total 7.555 19.422 9.154 4.45
Goodwill, Net 94.414 105.51
Deferred Income Tax 16.412 19.217
Other Current Liabilities, Total 32.6
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Total Current Assets 469.671 465.075 449.361 313.127 307.433
Cash and Short Term Investments 357.062 357.211 350.013 213.234 213.18
Cash & Equivalents 240.105 238.846 241.331 203.236 213.18
Total Receivables, Net 40.2 44.817 36.96 36.115 27.425
Accounts Receivable - Trade, Net 40.2 44.817 36.96 36.115 27.425
Total Inventory 66.067 55.765 57.827 58.412 61.876
Prepaid Expenses 6.342 7.282 4.561 5.366 4.952
Total Assets 665.691 659.353 632.278 514.088 525.571
Property/Plant/Equipment, Total - Net 12.917 12.998 13.503 13.828 13.707
Property/Plant/Equipment, Total - Gross 21.038 20.534 20.705 20.497 19.794
Accumulated Depreciation, Total -8.121 -7.536 -7.202 -6.669 -6.087
Goodwill, Net 96.581 94.414 86.942 94.852 102.558
Intangibles, Net 85.888 86.253 81.787 91.627 101.179
Other Long Term Assets, Total 0.634 0.613 0.685 0.654 0.694
Total Current Liabilities 66.17 65.247 60.843 29.859 25.519
Accounts Payable 14.737 9.07 9.972 10.207 10.39
Accrued Expenses 17.033 23.577 20.371 19.652 15.129
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases
Total Liabilities 89.085 89.214 82.76 76.362 62.139
Total Long Term Debt 0 0 0 0 0
Long Term Debt
Other Liabilities, Total 7.178 7.555 7.96 30.721 19.056
Total Equity 576.606 570.139 549.518 437.726 463.432
Common Stock 0.005 0.005 0.005 0.005 0.005
Additional Paid-In Capital 982.189 969.545 960.627 820.526 812.141
Retained Earnings (Accumulated Deficit) -383.512 -374.264 -374.929 -358.677 -337.234
Other Equity, Total -22.076 -25.147 -36.185 -24.128 -11.48
Total Liabilities & Shareholders’ Equity 665.691 659.353 632.278 514.088 525.571
Total Common Shares Outstanding 50.1107 49.5467 49.4796 47.1177 47.0029
Deferred Income Tax 15.737 16.412 13.957 15.782 17.564
Preferred Stock - Non Redeemable, Net 0 0 0 0 0
Short Term Investments 116.957 118.365 108.682 9.998
Other Current Liabilities, Total 34.4 32.6 30.5
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -59.698 -80.067 -54.915 -79.935 -32.483
Cash From Operating Activities 3.191 -47.306 -83.742 -83.454 -31.37
Cash From Operating Activities 11.721 9.126 1.741 1.191 0.946
Non-Cash Items 54.099 33.446 16.465 9.668 3.022
Cash Taxes Paid 0.667 0.001 0.001 0.001 0.001
Cash Interest Paid 0.001 2.178 1.102 1.436 0.751
Changes in Working Capital -2.931 -9.811 -47.033 -14.378 -2.855
Cash From Investing Activities -120.354 -143.002 9.654 45.287 -60.05
Capital Expenditures -2.223 -2.261 -2.938 -1.339 -1.228
Other Investing Cash Flow Items, Total -118.131 -140.741 12.592 46.626 -58.822
Cash From Financing Activities 133.968 170.513 144.19 110.955 165.342
Financing Cash Flow Items -0.192 -11.378 -9.013 -7.141 -12.292
Issuance (Retirement) of Stock, Net 134.16 208.007 153.203 118.096 157.634
Issuance (Retirement) of Debt, Net 0 -26.116 0 0 20
Foreign Exchange Effects 1.163 -0.508 -0.003 -0.012 -0.014
Net Change in Cash 17.968 -20.303 70.099 72.776 73.908
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -9.248 -59.698 -60.363 -44.111 -22.668
Cash From Operating Activities -0.781 3.191 -6.162 -10.009 -9.167
Cash From Operating Activities 2.813 11.721 8.841 5.92 3.029
Non-Cash Items 11.331 54.099 41.704 25.385 5.889
Cash Taxes Paid 0 0.667 0.644 0.639 0
Cash Interest Paid 0 0.001 0.001 0.001 0.001
Changes in Working Capital -5.677 -2.931 3.656 2.797 4.583
Cash From Investing Activities 0.694 -120.354 -110.324 -10.923 -0.291
Capital Expenditures -0.794 -2.223 -1.888 -0.925 -0.291
Other Investing Cash Flow Items, Total 1.488 -118.131 -108.436 -9.998 0
Cash From Financing Activities 1.93 133.968 133.807 1.924 1.444
Financing Cash Flow Items -0.192 -0.192 0 0
Issuance (Retirement) of Stock, Net 1.93 134.16 133.999 1.924 1.444
Issuance (Retirement) of Debt, Net 0 0 0 0
Foreign Exchange Effects -0.584 1.163 3.132 1.366 0.316
Net Change in Cash 1.259 17.968 20.453 -17.642 -7.698
Deferred Taxes

Axonics, Inc. Company profile

About Axonics Inc

Axonics, Inc. is a medical technology company. It is engaged in developing and commercializing products for patients with bladder and bowel dysfunction. The bladder and bowel dysfunction includes implantable sacral neuromodulation (SNM) systems to treat urinary urge incontinence (UUI) and urinary urgency frequency (UUF), together referred to as overactive bladder (OAB), as well as fecal incontinence (FI), and non-obstructive urinary retention (UR), and a urethral bulking agent to treat female stress urinary incontinence (SUI). It has designed and developed the rechargeable sacral neuromodulation (SNM) system (r-SNM System), which delivers mild electrical pulses to the targeted sacral nerve in order to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI. It has two relating to its r-SNM System, a European study, RELAX-OAB, and a United States pivotal study, ARTISAN-SNM. It offers urethral bulking agent, Bulkamid for stress urinary incontinence.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Axonics Inc revenues increased 62% to $180.3M. Net loss increased 46% to $80.1M. Revenues reflect United States segment increase of 55% to $166.5M, International segment increase from $4M to $13.8M. Higher net loss reflects Sales and marketing - Balancing value increase of 51% to $86.9M (expense), Research and development - Balancing va increase of 22% to $31.3M (expense).

Industry: Medical Devices & Implants

26 Technology Dr
IRVINE
CALIFORNIA 92618
US

News

EUR/USD tests key support

EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.

14:32, 21 September 2023
Bank of England building

BoE leaves rates unchanged, GBP drops further as investors look for more clarity

The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August

11:45, 21 September 2023
British banknotes and coins photographed directly above. The coins are in a stack, placed on top of the banknotes.

GBP softer after CPI surprise, JPY focused on any further hints from Ueda

GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.

12:42, 20 September 2023

How to Trade The Break & Retest

In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.

11:59, 20 September 2023

Cable coils near lows ahead of Fed and BoE rate decisions

It’s a big week for Cable (GBP/USD) as both the Federal Reserve and the Bank of England are set to make crucial rate decisions.

14:16, 19 September 2023

FTSE 100 Technical Outlook - 18 September 2023

In prior technical outlooks, we highlighted the importance of staying alert in sleepy markets, and last Thursday’s developments on the FTSE 100 serve as a prime illustration of this principle.

06:55, 19 September 2023
View of the City of London’s illuminated financial district skyline at dusk

Market Analysis: FTSE 100 boosted by ECB rate hike end and iron ore rally

The FTSE 100 rose over 2% on Thursday as the ECB announced no more rate hikes for now.

13:46, 15 September 2023

People also watch

Oil - Crude

90.41 Price
+0.950% 1D Chg, %
Long position overnight fee 0.0353%
Short position overnight fee -0.0572%
Overnight fee time 21:00 (UTC)
Spread 0.030

XRP/USD

0.52 Price
+0.240% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.01192

BTC/USD

26,677.35 Price
+0.180% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 85.00

US100

14,765.80 Price
+0.600% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0039%
Overnight fee time 21:00 (UTC)
Spread 1.8

Still looking for a broker you can trust?

Join the 555.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading